Everything the Food & Drug Administration does about Plan B makes headlines—but the commercial implications of the agency’s fitful handling of Barr Pharmaceuticals Inc. ’s over-the-counter switch application are harder to identify.
Now that FDA has approved the emergency contraceptive levonorgestrel for over-the-counter use in adults, Barr has a new avenue to ramp up sales—but it is hard to see how the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?